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Aims: To determine whether routine outpatient monitoring of growth predicts adrenal suppression in
prepubertal children treated with high dose inhaled glucocorticoid.
Methods: Observational study of 35 prepubertal children (aged 4–10 years) treated with at least 1000
mg/day of inhaled budesonide or equivalent potency glucocorticoid for at least six months. Main outcome
measures were: changes in HtSDS over 6 and 12 month periods preceding adrenal function testing, and
increment and peak cortisol after stimulation by low dose tetracosactrin test. Adrenal suppression was
defined as a peak cortisol (500 nmol/l.
Results: The areas under the receiver operator characteristic curves for a decrease in HtSDS as a predictor
of adrenal insufficiency 6 and 12 months prior to adrenal testing were 0.50 (SE 0.10) and 0.59 (SE 0.10).
Prediction values of an HtSDS change of 20.5 for adrenal insufficiency at 12 months prior to testing were:
sensitivity 13%, specificity 95%, and positive likelihood ratio of 2.4. Peak cortisol reached correlated
poorly with change in HtSDS (r=0.23, p = 0.19 at 6 months; r=0.33, p = 0.06 at 12 months).
Conclusions: Monitoring growth does not enable prediction of which children treated with high dose
inhaled glucocorticoids are at risk of potentially serious adrenal suppression. Both growth and adrenal
function should be monitored in patients on high dose inhaled glucocorticoids. Further research is required
to determine the optimal frequency of monitoring adrenal function.
A
significant proportion of asthmatic children are treated
with high dose inhaled glucocorticoids.1 Systemic side
effects of inhaled glucocorticoids in childhood asthma
have not been considered a problem at doses up to 400 mg/
day of budesonide (BUD) or beclomethasone dipropionate
(BDP) or equivalent,2–4 and reviews have questioned the
clinical relevance of adrenal suppression noted in children.5 6
However, there are recent case reports of symptomatic
adrenal suppression in asthmatic children treated with
moderate to high dose inhaled glucocorticoid.7–14 In some of
these patients the symptomatic adrenal suppression was
associated with normal linear growth.8 11 14 As asthma
guidelines recommend monitoring growth in children on
inhaled glucocorticoids,15 it is important to know whether
growth rate predicts which children have adrenal gland
suppression and need to carry a steroid card and take
glucocorticoid supplementation during stressful illness. In
this observational study of prepubertal asthmatic children
treated with high dose inhaled glucocorticoids and under-
going adrenal function testing, we related changes in height
standard deviation scores and body mass indices in the
previous 6 and 12 months to adrenal function.
METHODS
This was an observational study. Children 10 years of age or
younger attending specialist asthma clinics (1996 to 2002) at
the Royal Belfast Hospital for Sick Children or the local
Community Asthma Clinic who were identified as having
severe asthma requiring very high doses of inhaled gluco-
corticoids (equivalent to at least 1000 mg/day of BUD) for
more than six months were invited to take part. The age at
which they first started inhaled glucocorticoid therapy was
noted as was the duration of high dose therapy. They had no
other chronic medical conditions except eczema or allergic
rhinitis, and use of topical glucocorticoids was recorded. At
clinic visits inhaler technique was optimised and the dose of
inhaled glucocorticoid was tailored to current asthma
severity. Children requiring continuous oral steroids were
excluded. Informed parental consent was obtained for all
tests.
Growth measurements
Height standard deviation scores (HtSDS) and body mass
index standard deviation scores (BMISDS) were calculated
retrospectively 6 and 12 months before and at the time of
adrenal function testing. The change in HtSDS and change in
BMISDS were calculated for the 6 months (DHtSDS–
6 months, DBMISDS–6 months) and 12 months (DHtSDS–
12 months, DBMISDS–12 months) prior to adrenal function
testing. The height measurements were made on one of two
Holtain stadiometers by one of three trained nurses whose
measurement technique and measurement repeatability were
regularly audited.
Adrenal function tests
Adrenal function was tested by low dose tetracosactrin test
(0.5 mg/1.73 m2 body surface area) starting at 9 am. Advice
was given to omit inhaled glucocorticoid on the morning of
the test. If a child had received systemic glucocorticoids
within the past month adrenal function testing was delayed
for at least four weeks. Serum cortisol was measured at 0
(basal), 20, 30, 45, and 60 minutes. Cortisol was measured by
radioimmunoassay using reagents supplied by Diagnostic
Products Corporation, Los Angeles; the intracoefficient of
Abbreviations: HtSDS, height standard deviation score; BDP,
beclomethasone dipropionate; BMISDS, body mass index standard
deviation score; BUD, budesonide; FP, fluticasone propionate; IQR,
interquartile range; ROC, receiver operating characteristic; SE, standard
error
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variation for both assays was less than 7% for all levels. For
the purposes of statistical analysis cortisol concentrations
below the detection limit of 30 nmol/l were recorded as
20 nmol/l. There was no cross-reactivity of budesonide with
cortisol for the assay. Children were defined as having
adrenal suppression if, following tetracosactrin, a peak
cortisol >500 nmol/l was not reached.16–19 The number of
days for which each child required systemic prednisolone was
obtained from the case notes, general practitioner records,
and parental recall.
Statistical analysis
Descriptive statistics (median, interquartile range (IQR),
and range) were calculated for the basal serum cortisol, rise
in cortisol, peak cortisol level reached, and DHtSDSs and
DBMISDSs over the 6 and 12 month periods before adrenal
function testing. Spearman’s correlation coefficient (r) or
Pearson’s R (as appropriate) was used to determine the
association between DHtSDS and DBMISDS and adrenal
function. The Mann-Whitney U test was used to determine
whether DHtSDS or DBMISDS differed between those
with and without adrenal suppression. Sensitivity, specificity,
positive predictive values, and positive likelihood ratios
were calculated using DHtSDS for the prediction of adrenal
suppression. The area under the receiver operator character-
istic (ROC) curve (with standard error (SE)) was calculated
for DHtSDS. A p value of ,0.05 was considered significant.
RESULTS
Thirty seven children were identified and invited to undergo
adrenal function testing. Two parents refused to have the
adrenal function test performed leaving 35 children studied
(median age 8.6 years, IQR 7.3–9.6 years, range 4.2–10.6
years, 23 males). Fifteen had eczema and 15 allergic rhinitis,
of whom 11 were using topical glucocorticoids intermittently.
Twenty six were taking (FP) at doses ranging between 1000
and 2100 mg/day (median 1000 mg/day). Eleven used dry
powder at a median dose of 1000 mg/day and 16 used the
metered dose inhaler and spacer at a median dose of 1500 mg/
day. Nine children were treated with BUD by dry powder at
doses ranging from 1200 to 1600 mg/day (median 1600 mg/
day). All children had been on inhaled glucocorticoid for
more than two years. Thirty had been on high dose inhaled
glucocorticoid for more than 12 months and 25 for more than
24 months.
Attempts were made to reduce the dose of inhaled
glucocorticoid; some children had transient periods of
treatment with lower doses (lowest dose achieved was 750
mg/day for FP and 800 mg/day for BUD). In addition, three
children had periods when they were treated with nebulised
BUD (2–4 mg/day) either instead of or additional to their
usual inhaled glucocorticoid.
Twenty four children had been treated with at least one
course of systemic steroids (prednisolone 1–2 mg/kg/day) for
a median of 8 days (range 3–34 days) in total during the 12
months prior to adrenal function testing. DHtSDS and
DBMISDS were calculated over intervals of 0.5 (median
0.47, IQR 0.29–0.58) and 1.0 (median 1.1, IQR 1.0–1.4) years
before adrenal function testing. Table 1 summarises the
results for all patients and by inhaled glucocorticoid (FP,
BUD).
Sixteen (13 taking FP) of the 35 (46%) children had
evidence of biochemical adrenal suppression as defined
above. Four children on FP had both an undetectable basal
cortisol and no increase after tetracosactrin stimulation
(table 2).
No statistically significant differences in any of the growth
measures were observed in those with or without biochem-
ical adrenal suppression (table 3).
The correlations between peak cortisol and DHtSDS–
6 months (r=0.23, p=0.2) or DHtSDS–12 months
(r=0.33, p=0.06) and between peak cortisol and
DBMISDS–6 months (r=0.20, p=0.3) or DBMISDS–
12 months (r=0.32, p=0.07) were weak and not statisti-
cally significant.
The area under the ROC curves for DHtSDS–6 months and
DHtSDS–12 months in the prediction of biochemical adrenal
insufficiency were 0.50 (SE 0.10) and 0.59 (SE 0.10)
respectively (fig 1). Using a DHtSDS–12 months cut-off point
of 20.5 had a sensitivity of 13%, specificity of 95%, a positive
likelihood ratio of 2.4, and positive predictive value of 66% for
the prediction of adrenal suppression. Using a DHtSDS–
12 months cut-off point of 20.3 had a sensitivity of 25%,
specificity of 86%, a positive likelihood ratio of 1.7, and
positive predictive value of 60% for the prediction of adrenal
suppression.
Table 1 Summary results for all patients
All patients FP BUD
(n = 35) (n = 26) (n = 9)
DHtSDS–6 months
Median (IQR) 0.08 (20.09 to 0.23) 0.06 (20.04 to 0.23) 0.1 (20.2 to 0.2)
Range 20.37 to 0.55 20.32 to 0.55 20.37 to 0.23
DHtSDS–12 months
Median (IQR) 0.12 (20.14 to 0.31) 0.22 (20.1 to 0.31) 20.04 (20.34 to 0.34)
Range 20.65 to 0.45 20.63 to 0.45 20.65 to 0.45
DBMISDS–6 months
Median (IQR) 20.03 (20.44 to 0.35) 20.13 (20.46 to 0.25) 0.1 (20.03 to 0.62)
Range 21.5 to 0.97 21.5 to 0.72 20.77 to 0.97
DBMISDS–12 months
Median (IQR) 0.07 (20.46 to 0.58) 20.02 (20.53 to 0.58) 0.07 (20.36 to 0.67)
Range 21.4 to 2.62 21.4 to 2.62 21.4 to 1.0
Basal cortisol (nmol/l)
Median (IQR) 197 (87 to 275) 188 (50 to 254) 257 (150 to 302)
Range 20 to 514 20 to 514 20 to 328
Rise in cortisol (nmol/l)
Median (IQR) 258 (77 to 451) 249 (46 to 446) 260 (234 to 462)
Range 0 to 723 0 to 723 0 to 558
Peak cortisol (nmol/l)
Median (IQR) 533 (250 to 714) 472 (122 to 747) 570 (395 to 653)
Range 20 to 1103 20 to 1103 237 to 763
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DISCUSSION
We have found that DHtSDS at 6 and 12 months prior to
adrenal function testing does not predict adrenal suppression
in prepubertal asthmatic children treated with long term high
dose inhaled glucocorticoids. The DHtSDS–12 months was
the best measurement for predicting the presence of adrenal
suppression with an area under the ROC of 0.59. However,
the sensitivity of cut-off points (20.5 and 20.3) of DHtSDS
over 12 months were low at 13% and 25%, respectively,
indicating that many children with biochemical adrenal
suppression were not being detected.
Although endogenous and exogenous glucocorticoids are
potent suppressors of growth, the data presented show that
the routine monitoring of growth in children receiving high
dose inhaled glucocorticoids will not predict those with
adrenal suppression. Some children with normal growth
have potentially serious adrenal gland suppression and other
children with reduced growth have normal adrenal function.
This suggests that the systemic effects of glucocorticoids on
growth through the hypothalamic/pituitary/growth plate axis
are dissociated from the effects on the hypothalamic/
pituitary/adrenal cortex axis and the extent to which each
axis is affected varies between individuals. It is known that
high doses of glucocorticoids have a direct effect on growth
plate physiology,20 but in lower doses it is less clear what the
relation is. Any relation between inhaled glucocorticoids and
change in growth that could be used to predict adrenal
suppression is likely to be complex and to be influenced by
factors such as duration of treatment, differential tissue
sensitivity, and inter-individual sensitivity to glucocorticoids.
Concern following our initial case series7 lead us to invite
all asthmatic children who had been treated with inhaled
glucocorticoids (>1000 mg/day) at our clinics for longer than
six months to have adrenal function testing. Only two
parents declined. This study reports near complete data
ascertainment in a cohort of children with severe asthma
attending specialist asthma clinics during a 6–7 year period
where the prevalence of adrenal suppression (46%) was
sufficient to give meaningful results. Only prepubertal
children were included in an attempt to avoid the confound-
ing effect of puberty on growth rate.
One of three children reported by Todd et al, one of four
reported by Drake et al, and all three reported by Macdessi et
al apparently had normal growth at the time of experiencing
an adrenal crisis.8 11 14 The majority of the other reported
patients have had both growth and adrenal suppres-
sion.7 9 12 13 From these case reports and small case series it
is not possible to determine how frequently adrenal suppres-
sion occurs in a child with normal growth. It is likely that, in
at least some cases, adrenal function was tested only after
growth failure had been detected. A recent prospective one
year Finnish study of 75 newly diagnosed asthmatic children
aged 5.5–14.7 years, without previous exposure to inhaled
glucocorticoids, found that mild adrenal suppression devel-
oped in a quarter of the children treated with moderate doses
of inhaled glucocorticoids. Subnormal ACTH test results were
not associated with growth retardation during the first four
study months, but in children who used steroids for a year a
subnormal ACTH test at 4 months was associated with one
year growth suppression.21 We found a non-significant trend
for reduced growth at 12 months to be better than at 6
months for predicting adrenal suppression.
Height measurements can be problematic. To minimise
measurement error in our study the height measurements
were recorded on one of two stadiometers by one of three
trained nurses whose height measurement technique was
regularly audited. We used change in height standard
deviation score (DHtSDS) as an appropriate measure of
linear growth and superior to using height velocity standard
deviation scores which would have multiplied any measure-
ment errors incurred. We studied growth over 6 and 12
months prior to adrenal function testing, as making clinical
decisions on the basis of short term growth data may be
misguided.22
We have no indicator of how well the children were
complying with the inhaled glucocorticoid therapy and hence
did not analyse the data in detail for dose related effects. In
addition, we have no information on adrenal function in
Table 2 Summary of low dose tetracosactrin tests, age, HtSDS at time of test, and 12
months previous and inhaled corticosteroid (ICS) type and dosage in the four children with
the most severe adrenal suppression
Age
Basal
cortisol
Peak
cortisol ICS dose
HtSDS–
12 months
previously
HtSDS at time of
tetracosactrin
test(nmol/l) (nmol/l) (mg/m2/day)
Case 1 4.18 ,30 ,30 3030.3 0.09 20.54
FP via spacer
Case 2 8.14 ,30 ,30 520.8 0.71 20.32
FP via spacer
Case 3 7.88 ,30 ,30 1595.7 20.79 21.16
FP via spacer +
intermittent
nebulised BUD
Case 4 7.64 ,30 ,30 1456.3 0.84 0.34
FP via spacer
Table 3 Summary results for all categories
Adrenal suppression No adrenal suppression
(n = 16) (n = 19)
DHtSDS–6 months 0.06 (20.04 to 0.20) 0.1 (20.1 to 0.22) p = 0.97
DHtSDS–12 months 20.01 (20.34 to 0.35) 0.22 (20.09 to 0.31) p = 0.38
DBMISDS–6 months 20.35 (20.47 to 0.25) 0.06 (20.10 to 0.44) p = 0.14
DBMISDS–12 months 20.16 (20.50 to 0.58) 0.15 (20.30 to 0.77) p = 0.22
Results are reported as median (IQR).
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these children prior to our study period. All the children had
been on long term inhaled glucocorticoids, and the transient
reduction in growth velocity known to occur with initiating
therapy would already have been experienced and is there-
fore unlikely to have led to bias in our study.23 The majority of
previous studies and reviews on adverse effects of inhaled
glucocorticoids have considered growth and adrenal function
separately and have not reported information that allows an
estimate of having potentially severe adrenal suppression but
normal growth. Our study shows that potentially severe
adrenal suppression can occur in some asthmatic children
who are growing at a normal rate while taking high dose
inhaled glucocorticoids.
Inhaled glucocorticoids will continue to play a vital role in
the management of childhood asthma and it is important to
step down treatment when symptoms are controlled. We
agree with Carlsen and Gerritsen’s recommendation that all
children receiving high dose inhaled glucocorticoids should
have growth and adrenal function monitored.24 Further
research is necessary to elucidate the optimum frequency of
adrenal function testing and at what dose of inhaled
glucocorticoid usage is it required. With regards to the
frequency of testing adrenal function the study reported by
Nikolaizik et al is reassuring in that although nocturnal
cortisol production was significantly reduced by 19% after
one year of treatment, this was no greater than that observed
after two and four weeks’ treatment.25 However, their
patients were taking low to moderate doses of inhaled
glucocorticoids (400 mg/day), and they did not look at
adrenal reserve and therefore the capacity to respond to
stress. An alternative approach would be to assume that all
children on high dose inhaled glucocorticoid have adrenal
suppression, and to issue them with steroid cards and
recommend glucocorticoid supplementation during stressful
illness.
The Committee on Safety of Medicines recently reinforced
warnings regarding commonly used inhaled glucocorticoids,
advising that symptoms and signs of adrenal suppression
may be under recognised, particularly in children receiving
higher than licensed doses.26 Close attention must be paid to
treating asthmatic children with the minimum effective dose
of inhaled glucocorticoid to reduce the risk of adverse effects.
From our findings we conclude that monitoring growth
over a one year period in children requiring high dose inhaled
glucocorticoids is not an adequate screening test to identify
those with adrenal suppression.
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